Member Info for johnlaycock

Article I just posted mentions devote funding of 4.1m

Https://www.manchester.ac.uk/discover/news/lifesaving-bedside-stroke-test-receives-uk-product-safety-mark/

This is a big day for the company as they released their second pharmacogenomic test for emergency care, the Genedrive® CYP2C19 test. Anyone that doesn't recognise the significance of this, really doesn't understand how all this works. We should expect further news flow shortly on the roll out, beginning with the Manchester hospitals. Well done Mr Budd and the whole Genedrive team.

The Devote funding is excellent news for the company as it gives them funded access to real time evaluation of the Stroke product in critical care settings, which will hopefully allow a full NICE recommendation in December. They will only receive a small amount themselves but that was never the point of the grant .

Also EMQN (https://www.emqn.org/about-emqn/) are the companies partner in the Devote project and receive some funding too . The three projects are:

* Development of a rapid genetic bedside test to guide treatment for patients after stroke (Genedrive plc & EMQN).

* Using new and emerging biomaterials to develop an ultra-rapid genetic test, capable of detecting genetic changes to guide antibiotic therapy (Chromition Ltd and Epinal).

* Creation of a comprehensive pharmacogenetic testing panel with an informatic solution to ensure results are available to clinicians at the point of need (APIS Assay Technologies Ltd & EMQN).

Sorry but I've done more digging and the 2.1m grant is for the three devote projects of which Genedrive is one - the bulk of the 2.1m is going to the University of Manchester and the remainder is split between 4 organisations (Genedrive being 1). So it is going to make little impact on their cash but it will allow clinical evaluation of the stroke product in critical care units, which will be vital for NICE. approvals. To be fair to the company they did tell us in June that the bulk of the funding would go to the University of Manchester.

I think it looks like 2.1m to March 25?

https://gtr.ukri.org/

Put Genedrive in and it lists funding they have received - Devote is at the bottom. 2.1m or have I misread?

UKVI put me onto this Gateway in my recent FOI request.

Thoughts??

His salary in 2022 was 238k, bonus 30k and pension contributions 7k.

Won't he need to 'spike' the SP first?

Erm no Roger. Read the RNS on the funding grant details and given the funding description, it will be significantly more than 100k per annum.

I think we should hear very soon on the details of the devote grant and also hopefully UKCA approval.

Yes plenty to be updated on. New month tomorrow so let's hope the news flow starts soon.

Didn't you post yesterday?

Roger , you really do talk a lot of twaddle! So many inaccuracies in your latest essay and deliberately misleading....for instance the company has already told us they are not spending any money on future development of future assays but all monthly costs are devoted to the commercialisation of AIHL and the stroke test. Re RF they invest in companies they don't take them over. Do your research before posting false rumours!!!

Roger 65. The company cannot release exact details of their Devote funding grant yet because the projects have not been publicly announced by Innovate UK.

Who knows this could the week when positive news updates start happening?

Contradictions everywhere with SS. He may invest after another fundraise (he thinks in Dec and Jan) but then states they won't be selling anything for three years and won't break even for five. Utter drivel.

A lot will depend when the bull runs starts in the run up to the stroke NICE recommendation. But before end Nov anyway we should have lots of positive news updates anyway, so I think in the 35p to 40p range.

Stocksaint ...you seem to have conveniently forgotten that in the recent NICE guidance on future data collection, they clearly stated that funding would be available for further geographical roll outs of AIHL.

Roger, look at the overall number of RNS' on AIM this month compared with previous months. Its a fraction. This may come as a surprise to you but August is the quietest month for news, regulatory approvals, company updates etc etc.